查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715404

人体肝臟模型市场（按模型类型、细胞来源、应用和最终用户）—2025-2030 年全球预测

Human Liver Model Market by Model Type, Cell Source, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计人体肝臟模型市场规模在 2024 年将达到 15.5 亿美元，在 2025 年将达到 16.8 亿美元，在 2030 年将达到 25.4 亿美元，复合年增长率为 8.53%。

主要市场统计数据
基准年2024年 15.5亿美元
预计2025年 16.8亿美元
预测年份 2030 25.4亿美元
复合年增长率（%） 8.53%

过去十年来，人类肝臟模型的开发和完善速度大大加快，并已达到生物医学研究和药物开发的关键阶段。在精准医疗和创新治疗策略处于前沿的时代，深入了解肝臟模型变得至关重要。本报告深入探讨了肝臟模型的演变，研究了先进方法和新技术的整合，重新定义了肝臟生理学、疾病建模和毒性评估的方法。随着研究问题的不断升级和监管要求的不断加强，对忠实重现人类肝功能的模型的需求比以往任何时候都更加迫切。研究人员、临床医生和决策者都面临着复杂的选择，从传统的二维培养到动态的三维系统，每种系统都具有独特的优势并解决了传统方法的特定限制。目前的情况特征是向更复杂、生理相关的体外环境发生重大转变，这不仅受到技术创新的推动，也受到临床前试验中对可操作资料日益增长的需求的推动。在此背景下，该报告对人类肝臟模型研究未来的变革性转变、细分细微差别、区域趋势和关键参与者进行了系统性的研究。

推动肝臟建模技术发展的变革性转变

近年来，人类肝臟模型周围的环境正在发生重大变化。实验生物学、电脑模拟和生物工程的技术融合使得能够创建以前所未有的精度模拟人体肝臟复杂结构和功能的模型。组织工程的重大进展使研究人员能够建构比传统二维培养更好地包含细胞基质相互作用的三维结构。此外，体外和混合模型的整合透过将天然组织的真实性与工程系统的可控性相结合，弥合了传统的差距。In Silico模拟的出现进一步加速了资料分析和预测，允许即时调整和改进模型保真度。

这一转变的亮点是检验和最佳化的迭代过程，它现在已成为模型开发的一个组成部分。这使得新模型不仅成为药物发现和毒理学研究的有效平台，也成为生理学研究的有力工具。在技​​术方面，自动化和高通量筛检对加速这些进步做出了巨大贡献。随着研究不断完善其重现人类肝臟复杂行为的能力，向更俱生物学相关性的方法的模式转移也刺激了学术界、工业界和监管机构之间加强合作。此次合作凸显了该行业充满活力和动力的本质，该行业将持续的技术创新与严谨的科学探索相结合。

影响市场动态的关键细分洞察

深入研究细分可以发现一些对于定义市场动态和未来成长轨迹至关重要的基本趋势。根据模型类型分析市场，已经采用了各种不同的技术，包括 2D 模型、 3D模型、体外模型、混合构建体、电脑模型、肝臟类器官等等。每种模型在生物相关性和扩充性方面都具有独特的优势，使研究人员能够针对药物发现和毒理学研究中的特定问题。选择范围很广，从永生化肝细胞株和原代人类肝细胞到干细胞衍生模型，每种模型都有不同程度的生理准确性和可重复性。

此外，以应用为中心的细分凸显了这些模型的双重作用。虽然借助模拟代谢途径和讯号传递，药物发现仍然是一个主要的应用领域，但教育部门已从生理学和毒理学研究的进步中受益匪浅。这种双重关注促进了对肝功能的全面了解，并强调了透过真实世界资料增强的新的教育实践。此外，根据最终用户的细分，市场进一步分为生技公司、受託研究机构、製药公司和研究机构。最终用户概况的多样性不仅反映了这些模型在不同领域的广泛应用，也表明对适合每个细分市场特定要求的客製化肝臟模型的需求日益增长。这种多方面的細項分析将使相关人员能够识别量身定制的机会并准确地解决市场空白。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 增加政府和机构对生命科学和毒理学研究的资助
      • 对个人化医疗和针对患者的治疗方法的需求不断增加
      • 肝病及相关健康併发症的盛行率
    • 限制因素
      • 先进肝臟模型的开发和製造成本高昂
    • 机会
      • 投资和资助生物医学研究和创新肝臟模拟技术
      • 组织工程和3D生物列印解决方案的技术进步
    • 任务
      • 人体肝臟模型核准流程中的监管要求和合规障碍
  • 市场区隔分析
    • 模型类型：简单快速的筛检能力推动了 3D 人体肝臟模型的需求
    • 最终用户：生物技术公司越来越多地使用人体肝臟模型
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 人体肝臟模型市场（依模型类型）

  • 2D模型
  • 3D模型
  • 体外模型
  • 混合模式
  • In Silico模型
  • 肝臟类器官

7. 人类肝臟模型市场细胞来源

  • 永生化肝细胞株
  • 原代人类肝细胞
  • 干细胞衍生模型

8. 人体肝臟模型市场（依应用）

  • 药物研发
  • 教育
    • 生理学研究
    • 毒理学研究

9. 人体肝臟模型市场（依最终用户）

  • 生技公司
  • 合约研究组织
  • 製药公司
  • 研究部门

10.美洲人体肝臟模型市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11.亚太地区人体肝臟模型市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12.欧洲、中东和非洲人体肝臟模型市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Ascendance Bio
  • BioIVT LLC
  • Cellink Global by BICO Group AB
  • CN Bio Innovations Ltd.
  • Corning Incorporated
  • Cyfuse Biomedical KK
  • EISCO Scientific LLC
  • Emulate Inc.
  • Hurel Corporation
  • InSphero AG
  • Kirkstall Ltd
  • MIMETAS BV
  • NeurOmics, Inc.
  • Organovo Holdings Inc.
  • Pandorum Technologies Private Limited
  • PhoenixBio Co., Ltd.
  • STEMCELL Technologies Inc.
Product Code: MRR-43127F7278DC

The Human Liver Model Market was valued at USD 1.55 billion in 2024 and is projected to grow to USD 1.68 billion in 2025, with a CAGR of 8.53%, reaching USD 2.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.55 billion
Estimated Year [2025] USD 1.68 billion
Forecast Year [2030] USD 2.54 billion
CAGR (%) 8.53%

The development and refinement of human liver models has accelerated dramatically over the past decade, marking a pivotal moment in biomedical research and drug development. In an era where precision medicine and innovative therapeutic strategies are at the forefront, an in-depth understanding of liver models has become essential. This report delves into the evolution of liver models, examining the integration of advanced methodologies and emerging technologies that are redefining the approach to liver physiology, disease modeling, and toxicity assessment. As research challenges escalate and regulatory demands intensify, the need for models that closely replicate human liver functions is more urgent than ever. Researchers, clinicians, and decision-makers alike are now presented with sophisticated alternatives-ranging from traditional two-dimensional cultures to dynamic three-dimensional systems, each offering unique benefits and addressing specific limitations of conventional methods. The current landscape is characterized by a significant shift towards more complex and physiologically relevant in vitro environments, a transition driven by both technological ingenuity and an increasing demand for actionable data in preclinical testing. In this context, this report provides a structured exploration of the transformative shifts, segmentation nuances, regional trends, and key players that are collectively steering the future of human liver model research.

Transformative Shifts Driving the Evolution of Liver Model Technologies

Recent years have witnessed transformative shifts that are reshaping the human liver model landscape. Technological convergence in experimental biology, computational simulations, and bioengineering has led to the creation of models that mimic the complex architecture and functionality of the human liver with unprecedented accuracy. Significant advancements in tissue engineering have enabled researchers to build three-dimensional constructs that encapsulate cell-matrix interactions better than traditional two-dimensional cultures. Additionally, the integration of ex vivo and hybrid models has bridged conventional gaps by combining the realism of native tissue with the controllability of engineered systems. The advent of in silico modeling has further accelerated data analysis and prediction, allowing for real-time adjustments and improvements in model fidelity.

A noteworthy element in these transformative shifts is the iterative process of validation and optimization that is now integral to model development. This ensures that emerging models not only serve as effective platforms for drug discovery and toxicology studies but also provide robust tools for physiological investigations. On the technological front, automation and high-throughput screening have contributed heavily to accelerating these advances. As research continues to drive improvements in replicating the human liver's complex behavior, the paradigm shift towards more biologically relevant methods is also fueling increased collaboration between academia, industry, and regulatory agencies. These converging forces underscore the vibrant, dynamic nature of the industry, where continuous innovation meets rigorous scientific inquiry.

Key Segmentation Insights Shaping Market Dynamics

A deep dive into segmentation reveals several underlying trends that are instrumental in defining market dynamics and future growth trajectories. When analyzing the market based on model types, an array of distinct technologies is employed, including two-dimensional models, three-dimensional models, ex vivo models, hybrid constructs, in silico models, and liver organoids. Each model brings its own set of advantages in terms of biological relevance and scalability, enabling researchers to target specific challenges in drug discovery and toxicology studies. Complementarily, a segmentation based on cell source further distinguishes the market; choices range from immortalized liver cell lines and primary human hepatocytes to stem cell-derived models, each offering varying levels of physiological accuracy and reproducibility.

In addition, application-centric segmentation highlights the dual role of these models. While drug discovery remains a major application area-supported by the ability to simulate metabolic pathways and signaling cascades-the educational sector has significantly benefited from advancements in physiology and toxicology studies. This dual focus facilitates a comprehensive understanding of liver functionality and underlines new educational practices enhanced by real-world data. Moreover, the segmentation based on end users further segments the market into biotechnology companies, contract research organizations, pharmaceutical companies, and research laboratories. The diversity in end-user profiles not only reflects a broad adoption of these models across various sectors but also illustrates the growing need for tailored liver models that match the specific requirements of each segment. This multifaceted segmentation analysis ensures that stakeholders can identify tailored opportunities and address market gaps with precision.

Based on Model Type, market is studied across 2D Models, 3D Models, Ex Vivo Models, Hybrid Models, In Silico Models, and Liver Organoids.

Based on Cell Source, market is studied across Immortalized Liver Cell Lines, Primary Human Hepatocytes, and Stem Cell-Derived Models.

Based on Application, market is studied across Drug Discovery and Education. The Education is further studied across Physiological Studies and Toxicology Studies.

Based on End Users, market is studied across Biotech Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Laboratories.

Regional Analysis: Global Perspectives on the Liver Model Sector

Regional dynamics play a critical role in shaping the development and adoption of human liver models. Market analysis indicates that different regions are prioritizing different aspects of technological advancement and regulatory frameworks. For instance, in the Americas, robust investment in biotechnology and healthcare infrastructure has paved the way for rapid adoption of innovative liver models in both industrial and academic settings. The mature ecosystem in this region supports a high level of collaboration among stakeholders, driving advancements through coordinated research and development efforts.

In contrast, the combined regions of Europe, the Middle East, and Africa are witnessing tailored investments designed to overcome regional healthcare challenges while balancing ethical and regulatory considerations. In these areas, traditional research methodologies are increasingly giving way to more sophisticated, hybrid approaches that integrate both ex vivo and in silico techniques. Meanwhile, the Asia-Pacific region stands out for its focused emphasis on scalability and cost-effectiveness. Rapid economic growth coupled with an expansive network of research institutions has catalyzed new product development and increased the overall global footprint of human liver models. Taken together, these regional insights underscore how localized market forces and strategic investments shape the adoption of liver models across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Spotlight: Leading Industry Players in Liver Modeling

The competitive landscape of liver model development is marked by the presence of several forward-thinking companies that are redefining the field. Industry leaders such as Ascendance Bio and BioIVT LLC have emerged as innovator hubs, consistently pushing the boundaries of technology. Significant contributions from companies like Cellink Global by BICO Group AB and CN Bio Innovations Ltd. have brought advanced tissue engineering capabilities into sharper focus, while established names such as Corning Incorporated demonstrate an enduring commitment to quality and reliability. Equally, Cyfuse Biomedical K.K. and EISCO Scientific LLC are gaining traction by offering novel approaches to bioprinting and model validation, thereby reinforcing the need for highly physiologically relevant systems.

Other key players, including Emulate Inc., Hurel Corporation, and InSphero AG, have systematically integrated emerging technologies to enhance model precision and usability. Companies like Kirkstall Ltd, MIMETAS B.V., and NeurOmics, Inc. are notable for their contributions toward merging traditional cell culture techniques with state-of-the-art engineering innovations. Organovo Holdings Inc. and Pandorum Technologies Private Limited have also been instrumental in redefining biological fabrication for comprehensive tissue modeling. Additionally, PhoenixBio Co., Ltd. and STEMCELL Technologies Inc. ensure that continuous product enhancements keep pace with evolving research demands. The cumulative impact of these organizations reflects a market driven by relentless innovation and vigorous competition, fostering an environment where quality, reliability, and scalability are equally prioritized.

The report delves into recent significant developments in the Human Liver Model Market, highlighting leading vendors and their innovative profiles. These include Ascendance Bio, BioIVT LLC, Cellink Global by BICO Group AB, CN Bio Innovations Ltd., Corning Incorporated, Cyfuse Biomedical K.K., EISCO Scientific LLC, Emulate Inc., Hurel Corporation, InSphero AG, Kirkstall Ltd, MIMETAS B.V., NeurOmics, Inc., Organovo Holdings Inc., Pandorum Technologies Private Limited, PhoenixBio Co., Ltd., and STEMCELL Technologies Inc.. Recommendations for Industry Leaders to Capitalize on Emerging Trends

Industry leaders are encouraged to adopt a multi-pronged strategy to harness the burgeoning opportunities in the human liver model sector. First, it is essential to invest in interdisciplinary collaborations that fuse expertise in tissue engineering, computational biology, and regenerative medicine. Such collaborations not only spur breakthrough innovations but also facilitate broader adoption of models that accurately mirror human physiology. Embracing state-of-the-art automation and high-throughput screening technologies will further enhance model reproducibility and accelerate preclinical studies, making your operations more competitive in the ever-evolving market landscape.

Second, consider targeting innovative product portfolio expansion strategies. Leveraging insights from advanced segmentation analyses-including model types, cell sources, application fields, and end-user profiles-can pinpoint specific market opportunities. Industry players who customize their offerings to meet sector-specific needs-whether for drug discovery or educational applications-will likely gain a strategic advantage. Additionally, scaling by addressing regional nuances is recommended; tailored regional partnerships or localized research initiatives can help capitalize on the distinct market dynamics present in the Americas, Europe, the Middle East and Africa, as well as the Asia-Pacific.

Finally, adopting rigorous validation protocols and pursuing regulatory alignment is paramount. Clear standards in model performance and reproducibility not only build trust with stakeholders but also pave the way for smoother market entry and integration into regulatory frameworks. By proactively engaging with these strategic imperatives, industry leaders will be well-positioned to drive innovation, secure market leadership, and better address emerging global health challenges.

Conclusion and Future Outlook for Human Liver Model Research

In conclusion, the advances in human liver modeling are reshaping the landscape of biomedical research and drug development. The integration of innovative techniques, from two-dimensional cultures to complex three-dimensional organoids and in silico platforms, is enabling breakthroughs that were once considered unattainable. As the market becomes increasingly segmented-by model types, cell sources, applications, and end-user demographics-the industry is poised for significant growth and diversification.

The analysis illustrates that transformative shifts are fueled by relentless innovation, cross-disciplinary collaborations, and regional strategic investments. Technological advancements in automation, high-throughput screening, and tissue engineering have raised the bar, ensuring that the models not only replicate key liver functions but also offer enhanced utility in toxicity and physiological studies. The competitive landscape, which features a blend of established giants and nimble startups, continues to drive the evolution of liver models, creating a robust foundation that supports next-generation drug discovery and clinical research.

Looking ahead, continued investments in research, a focus on scalable solutions, and adherence to robust regulatory standards will be critical. By recognizing and leveraging emerging trends, industry stakeholders will be able to navigate an increasingly complex market with precision and confidence, establishing pathways for sustained innovation and growth in the years to come.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising government and institutional funding for life sciences and toxicological studies
      • 5.1.1.2. Increase in demand for personalized medicine and patient-specific therapies
      • 5.1.1.3. Escalating prevalence of liver diseases and associated health complications
    • 5.1.2. Restraints
      • 5.1.2.1. High development and manufacturing costs of advanced liver models
    • 5.1.3. Opportunities
      • 5.1.3.1. Investments & funding in biomedical research and innovative liver simulation technologies
      • 5.1.3.2. Technological advances in tissue engineering and 3D bioprinting solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory requirements and compliance obstacles in the human liver model approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Model Type: Rising demand for 3D human liver model for their simplicity and rapid screening capabilities
    • 5.2.2. End Users: Growing usage of human liver model in biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Liver Model Market, by Model Type

  • 6.1. Introduction
  • 6.2. 2D Models
  • 6.3. 3D Models
  • 6.4. Ex Vivo Models
  • 6.5. Hybrid Models
  • 6.6. In Silico Models
  • 6.7. Liver Organoids

7. Human Liver Model Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Immortalized Liver Cell Lines
  • 7.3. Primary Human Hepatocytes
  • 7.4. Stem Cell-Derived Models

8. Human Liver Model Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Discovery
  • 8.3. Education
    • 8.3.1. Physiological Studies
    • 8.3.2. Toxicology Studies

9. Human Liver Model Market, by End Users

  • 9.1. Introduction
  • 9.2. Biotech Companies
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies
  • 9.5. Research Laboratories

10. Americas Human Liver Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Liver Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Liver Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Ochre Bio and GSK join forces to accelerate hepatology drug discovery
    • 13.3.2. Boehringer Ingelheim and Ochre Bio partner to accelerate regenerative liver therapy discovery
    • 13.3.3. PhoenixBio's innovative humanized liver chimeric mouse models transform preclinical drug testing
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Ascendance Bio
  • 2. BioIVT LLC
  • 3. Cellink Global by BICO Group AB
  • 4. CN Bio Innovations Ltd.
  • 5. Corning Incorporated
  • 6. Cyfuse Biomedical K.K.
  • 7. EISCO Scientific LLC
  • 8. Emulate Inc.
  • 9. Hurel Corporation
  • 10. InSphero AG
  • 11. Kirkstall Ltd
  • 12. MIMETAS B.V.
  • 13. NeurOmics, Inc.
  • 14. Organovo Holdings Inc.
  • 15. Pandorum Technologies Private Limited
  • 16. PhoenixBio Co., Ltd.
  • 17. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN LIVER MODEL MARKET MULTI-CURRENCY
  • FIGURE 2. HUMAN LIVER MODEL MARKET MULTI-LANGUAGE
  • FIGURE 3. HUMAN LIVER MODEL MARKET RESEARCH PROCESS
  • FIGURE 4. HUMAN LIVER MODEL MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN LIVER MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN LIVER MODEL MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY HYBRID MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 238. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 239. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024